• Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC)
  • The CTMC will use the company’s AI engine CARA to begin screening Colombia’s population for eye-related issues
  • CARA (Computer Assisted Retina Analysis) integrates with existing equipment, and makes standard retinal images sharper, clearer, and easier to read
  • The two parties plan to begin the screening project in two major regions of Colombia in the following weeks
  • Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share 

Medical technology company, DIAGNOS (ADK) has revealed a new service agreement with the Colombian Telemedicine Centre (CTMC).

The CTMC has chosen DIAGNOS and its artificial intelligence engine, CARA, for a screening project. In alliance with the country’s largest specialist centre, the CTMC will use CARA to screen Colombia’s population for eye-related issues.

The CTMC’s founder, Dr Jorge Alberto Velez B, said this will unburden the heavy costs of blindness caused by diabetes.

CARA (Computer Assisted Retina Analysis) is a tele-ophthalmology platform that integrates with pre-existing hardware or software. The tool’s image enhancement algorithms make standard images of a person’s retina sharper, clearer, and easier to read. 

CARA can process results at the point of care, which will empower local technicians. However, specialists will validate the automated results before scheduling follow-ups with patients requiring further treatment.  

The CTMC and DIAGNOS plan to start the screening project in two major regions of Colombia, in the coming weeks.

DIAGNOS’ President, André Larente, commented on the service agreement with Colombia’s Telemedicine Centre. 

“We would like to thank the CTMC for choosing our CARA platform. We believe that CARA is a perfect fit as the main engine of the telemedicine solution.

“After a successful eye screening program with Bayer in 2015, we return to Colombia to engage our AI service into a practical solution for the local community. Along with CTMC, we can add value by making our unique service accessible,” he said. 

Before the market opens, DIAGNOS (ADK) is trading at C$0.17 per share.

More From The Market Online

BriaCell reports survival data from Phase 2 study

BriaCell Therapeutics (TSX:BCT) reveals new positive survival data in its Phase 2 metastatic breast cancer study.
doctor pointing finger to CT scans

Quantum BioPharma sues CIBC and RBC seeking $700M in damages

A U.S. legal firm claims it has evidence of a market manipulation scheme that caused substantial damages to Quantum BioPharma (CSE:QNTM).

Datametrex AI and CEO part ways amid poor stock performance

Datametrex AI (TSXV:DM) CEO Marshall Gunter resigns following the company's poor financials and stock performance.
WELL Health founder and CEO Hamed Shahbazi, centre.

WELL subsidiary launches support for women’s hormonal imbalance

WELL Health (TSX:WELL) subsidiary Wisp, the United States' largest dedicated women's telehealth provider, launches a weight care vertical.